Eclectic Wealth

Repros Therapeutics: Winning The Battle But Losing The War?

Repros Therapeutics: Winning the Battle but Losing the War?


Repros Therapeutics (NASDAQ:RPRX) is developing a drug named Androxal that targets raising testosterone in men. Repros is developing several other drugs for different purposes, however Androxal's prospects are driving much of the near-term expectations for Repros's valuation. Androxal is often projected to capture a significant share of the Testosterone replacement market if approved due to perceived advantages for Androxal related to preserving fertility and ease of use in comparison to testosterone replacement based on injections or other forms of supplemental Testosterone. The case for the likely approval of Androxal has been well-described by other SA authors and if anything, I believe the case for approval is even stronger...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details